CCCC NASDAQ
C4 Therapeutics, Inc.
1W: -1.0%
1M: -22.2%
3M: -28.7%
YTD: +52.9%
1Y: +37.2%
3Y: +63.0%
5Y: -94.0%
$2.95
-0.19 (-6.05%)
Weekly Expected Move ±7.7%
$2
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2023-05-30
Earliest Filing
2023-12-12
Latest Filing
partner: 2
investor: 1
Counterparties (Filed by CCCC)
3 relationshipsCompanies named in CCCC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | MRK | partner | Entered into a License and Collaboration Agreement with C4 Therapeutics, Inc. to develop and commercialize degrader-anti | 2023-12-12 | View |
| Betta Pharmaceuticals Co., Ltd. | — | partner | Partnered with C4 Therapeutics for exclusive license and collaboration on CFT8919 in China/Hong Kong/Macau/Taiwan | 2023-05-30 | View |
| Betta Investment (Hong Kong) Limited | — | investor | Affiliate of Betta Pharma that purchased $25 million of C4 Therapeutics common stock | 2023-05-30 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-25 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-06-24 | Shareholder Vote; Exhibits | View | |
| 2026-06-11 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-15 | Officer/Director Change | View | |
| 2026-05-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-10 | Bylaws Amendment; Exhibits | View | |
| 2026-04-09 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-16 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-10-16 | Other Events | View | |
| 2025-10-01 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-22 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-06-18 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-04-14 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR